Non-Hodgkin’s Lymphoma

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Winning the Battle Against Lymphoma

There are many types and subtypes of lymphoma, each requiring a specialized treatment. Lymphoma patients who choose Seattle Cancer Care Alliance (SCCA) receive expertly targeted and delivered care, along with access to new therapies explored in clinical studies conducted at SCCA and its founding organizations, Fred Hutch and UW Medicine.

Statistics Are Abstract; Lives Aren’t

Susan Ault, Lymphoma Survivor Susan Ault moved to the Pacific Northwest to get treatment for her lymphoma at SCCA. Now a survivor, she’s taken up permanent residence in Sequim. Read more about Susan.

If you do have lymphoma, where you choose to go for initial treatment has a significant impact on your likelihood of survival. Lymphoma patients at SCCA have access to advanced therapies and treatments being explored in several dozen ongoing clinical trials for lymphoma conducted at Fred Hutch and UW Medicine. For people with lymphoma who are good candidates for stem cell transplants, the Fred Hutch Transplant Program at SCCA is the most experienced transplant center in the world. As you can see below, patients treated for lymphoma at SCCA have high five-year survival rates.

Lymphoma Survival Rates

Below are the five-year survival rates for lymphoma patients treated by SCCA compared to patients who were treated for lymphoma elsewhere. This information was collected by the National Cancer Data Base (NCDB) for patients who were diagnosed and treated between 2003 and 2006 and then followed for five years.

Stage I Lymphoma

  • SCCA patients are represented by the green line. Their five-year survival rate was 82 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their five-year survival rate was 71 percent.

Stage II Lymphoma

  • SCCA patients are represented by the green line. Their five-year survival rate was 88 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their five-year survival rate was 65 percent.

Stage III Lymphoma

  • SCCA patients are represented by the green line. Their five-year survival rate was 63 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their five-year survival rate was 58 percent.
  • Note: While the SCCA survival rates appear to be better for stage III lymphoma, the data could not be statistically validated.

Stage IV Lymphoma

  • SCCA patients are represented by the green line. Their five-year survival rate was 72 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by the yellow line. Their combined five-year survival rate was 49 percent.

The charts above include patients who were diagnosed between 2003 and 2006 and then followed for five years. The five-year observed survival rates are estimated using the actuarial method with one-month intervals. The endpoint is death from any cause (not cancer specific death); patients may have died from causes unrelated to their cancer. Calculations were performed using the NCDB Survival Reports software tool. Survival rates are not displayed when fewer than 30 cases are available, as survival rates calculated from small numbers of cases can yield misleading results and may have very wide confidence intervals.

The outcomes presented in the figures are not risk-adjusted. That is, the NCDB did not account for demographic differences (e.g., age at diagnosis, gender, socioeconomic status, and insurance status), prognostic factors, and comorbidities for SCCA and other hospitals. Also, the NCDB did not account for subjective differences in staging practices among hospitals. For example, it is possible that a cancer considered stage I at one hospital might be considered stage II at another hospital due to practice pattern variations. The outcomes comparisons presented here might have differed if the NCDB had accounted for such demographic and staging differences in our analyses.

The NCDB tracks the outcomes of 70 percent of all newly diagnosed cancer in the United States from more than 1,500 commission-accredited cancer programs. It has been collecting data from hospital cancer registries since 1989 and now has almost 30 million records.

Frequently Asked Questions

Data Collection Methodology